ReviewLife (Basel, Switzerland)2021
The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 193 citations in OpenAlex.
- Association of atopic diseases with atrial fibrillation risk: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Topical Applications of Sodium Taurodeoxycholate, a Treatment for Atopic Dermatitis.Clinical and translational science · 2025Trial
- Identifying and addressing obstacles to optimal alopecia areata and atopic dermatitis care in the UK.Skin health and disease · 2026Article
- Nailfold Capillaroscopic Changes in Children with Atopic Dermatitis.Journal of clinical medicine · 2026Article
- Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.Dermatology and therapy · 2026Review
- Timing of Allergenic Food Introduction in Infants, Saudi Arabia: A Cross-Sectional Study.Nutrients · 2026Article
- Article
- Contribution of Immune Responses toJournal of inflammation research · 2026Article
- A Multicenter Cross-Sectional Study on Clinical Characteristics and Disease Burden of 1010 Patients with Moderate to Severe Atopic Dermatitis in Chinese Tertiary Hospitals.Clinical, cosmetic and investigational dermatology · 2026Article
- The mRNA levels ofPostepy dermatologii i alergologii · 2026Article
- Genome-wide cross-trait analysis of heterogeneous outcomes in early life atopic dermatitis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Targeting Pollutants in the Treatment and Prevention of Atopic Dermatitis.Immunology and allergy clinics of North America · 2025Review
- FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older.Annals of medicine and surgery (2012) · 2025Article
- Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: A Systematic Review.Cureus · 2025Review
- Magnitude of atopic dermatitis and associated factors among children in northwest Ethiopia.Scientific reports · 2025Article
- Article
- Article
- Long-term investigation of 3D tissue detailed structure and multiparametric vascular network properties using OCT/OCTA for guiding atopic dermatitis theranostics.Journal of translational medicine · 2025Article
- Knowledge assessment tools in atopic dermatitis patient education: a scoping review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global epidemiology of atopic dermatitis (AD) in the current decade (2009-2019) has not been extensively reported. Epidemiological studies play an important role in presenting the risk factors of AD, as detailed prevalence and incidence data could demonstrate the burden of disease in the population of adults, adolescents, and children in different geographical regions. Thus, the primary objective of this review was to assess and summarize the epidemiological studies of the prevalence and incidence of AD in different age groups, focusing on data from studies published for 2009 to 2019. After a thorough literature search, six countries were identified from African, Asian, and European regions respectively, who published studies on AD. In contrast, only two studies were identified from Australia and New Zealand, three countries from North America and two from South America published AD studies, respectively. The highest prevalence of AD from included studies was noted among Swedish children with 34%, while the lowest prevalence was in Tunisian children with 0.65%; studies reporting incidence data were far less numerous. A common trend in the prevalence of AD was that children would have a higher prevalence as compared to adolescents and adults. The severity and morbidity of the disease showed variance with age, sex, socioeconomic characteristics, geographical location, and ethnicity. Environmental factors played an important role as causative agents in AD. The risk factors that were proven to cause and induce AD were skin barrier impairments due to FLG mutation, changes in the environment, and diet. FLG mutation may impair the skin barrier function by disruption of pH and hydration maintenance of the skin. Lastly, there were only a few studies on the incidence of AD in the 21st century. Therefore, epidemiological studies on childhood and adulthood AD in different continents are still needed, especially on the incidence of AD during adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.